Was Vitravene (fomivirsen) ever discontinued, and what does the FDA Orange Book say?
Vitravene (fomivirsen) was discontinued. The FDA’s Orange Book records the status of approved drug products and their exclusivity/patent information, but the key point for your question is that Vitravene is no longer marketed because the product was discontinued.
How do I confirm the exact Orange Book entry and discontinued status?
To verify this for the specific product listing, you can search the FDA Orange Book for:
- Drug name: “Vitravene” or “fomivirsen”
- Applicant/manufacturer name (if shown in the listing)
- Strength and dosage form (if multiple entries exist)
The Orange Book entry for a discontinued product will typically reflect that it is not currently marketed (the Orange Book is designed to show approved products and related patent/exclusivity information, not just active sales).
Why was Vitravene discontinued (common real-world driver)?
Although the Orange Book mainly reflects regulatory and patent/exclusivity status, Vitravene’s discontinuation is generally tied to changes in how cytomegalovirus (CMV) infections—its target use—were treated over time, including the adoption of other CMV therapies. That reduced demand for fomivirsen and ultimately led to discontinuation.
What does “discontinued” mean for patients now?
If a drug is discontinued, it is typically not available through routine commercial channels. Patients who previously used it would need alternative therapies authorized for their condition, selected by their clinicians and guided by current prescribing information and clinical practice.
Are there other fimivirsen products or replacements?
For CMV treatment, clinicians use other approved antiviral strategies depending on the patient’s situation (site of infection, severity, immune status). If you tell me the condition (for example, CMV retinitis vs. another form), I can help map which alternatives are commonly used.
If you want, paste the Orange Book link or the exact listing (strength/dosage form) you’re looking at, and I can interpret what the Orange Book indicates for that specific entry.
Sources:
1. DrugPatentWatch.com (Vitravene/fomivirsen listings and related patent/exclusivity context): https://www.drugpatentwatch.com/